Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

References

• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AT, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   Google Scholar
• ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   Google Scholar
• Duckworth W, for the VADT Study Group. Results of the VA Diabetes Trial. Presented at the 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, June 8, 2008
   Google Scholar
• Schneider CA. Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. Curr Med Res Opin 2006;22(Suppl. 2):S15-S26
   PubMed Web of Science ®Google Scholar
• Das SK, Elbein SC. The genetic basis of type 2 diabetes. Cell Science 2006;2:100-31
   Google Scholar
• Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6
   PubMed Web of Science ®Google Scholar
• Müller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15
   PubMed Web of Science ®Google Scholar
• Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004;17:183-90
   Google Scholar
• Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and implications. Clin Ther 2005;27(Suppl. B):S42-S56
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Fuecker K, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003;26:868-74
   PubMed Web of Science ®Google Scholar
• Genuth S, Kahn R. A step backward – or is it forward? Diabetes Care 2008;31:1093-6
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003;26:881-5
   PubMed Web of Science ®Google Scholar
• Barr ELM, Boyko EJ, Zimmet PZ, et al. Two-hour glucose predicts the development of hypertension over five years: the AusDiab study. 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD). Amsterdam, The Netherlands, September 13–17, 2007 [abstract 290]
   Google Scholar
• DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405
   PubMed Web of Science ®Google Scholar
• Brindisi MC, Rabasa-Lhoret R, Chiasson JL. Postprandial hyperglycemia: to treat or not to treat? Diabetes Metab 2006;32:105-11
   Google Scholar
• Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-8
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006;6:194-201
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20
   PubMed Web of Science ®Google Scholar
• Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997;160:413-22
   PubMedGoogle Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
   PubMed Web of Science ®Google Scholar
• Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
   PubMed Web of Science ®Google Scholar
• Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-52
   PubMed Web of Science ®Google Scholar
• Program for the Management of Diabetes, University of Pennsylvania Health System Intranet, updated 2007. http://uphsxnet.uphs.upenn.edu/ceqi/clininfo/outpa/diabetes.html [accessed January 2008]
   Google Scholar
• Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 2006;10:349-60
   PubMed Web of Science ®Google Scholar
• Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003;17:662-76
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. For the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
   PubMed Web of Science ®Google Scholar
• Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006;15:243-50
   PubMed Web of Science ®Google Scholar
• Patel CB, De Lemos JA, Wyne KL, et al. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR gamma agonism. Diab Vasc Dis Res 2006;3:65-71
   PubMedGoogle Scholar
• Göke B, Lübben G, Bates P, on behalf of the German Pioglitazone Study Group. Coefficient of β-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. Exp Clin Endocrinol Diabetes 2004;112:115-7
   PubMed Web of Science ®Google Scholar
• Füllert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, et al. for the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
   PubMed Web of Science ®Google Scholar
• Mohanty P, Aliada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
   PubMed Web of Science ®Google Scholar
• Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954-7
   PubMed Web of Science ®Google Scholar
• Deeg MA, Buse JB, Goldberg RB, et al., for the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-64 [epub 2007 June 26]
   Google Scholar
• Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
   PubMed Web of Science ®Google Scholar
• Steg PG, Marre M. Does PERISCOPE provide a new perspective on diabetic treatment? J Am Med Assoc 2008;299:1603-4
   Web of Science ®Google Scholar
• Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 2006;6:297-304
   PubMedGoogle Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
   PubMed Web of Science ®Google Scholar
• Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006;49:452-8
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61
   PubMed Web of Science ®Google Scholar
• Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-13
   PubMed Web of Science ®Google Scholar
• Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-35
   PubMed Web of Science ®Google Scholar
• Thrainsdottir I, Malmberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004;1:40-3
   PubMedGoogle Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3:159-65
   PubMedGoogle Scholar
• Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidylpeptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the DPP-4 inhibitor sitagliptin and pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
   PubMed Web of Science ®Google Scholar
• Stein PP, Williams-Herman D, Khatami H, et al. Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with type 2 diabetes: pooled analysis of 5141 patients in clinical trials for up to 2 years. 67th Scientific Sessions of the American Diabetes Association. Chicago, Illinois, June 22–26, 2007 [poster 534-P]
   Google Scholar
• Januvia [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.; 2007
   Google Scholar
• Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
   PubMed Web of Science ®Google Scholar
• Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomized studies. Int J Clin Pract 2004;58:907-12
   PubMed Web of Science ®Google Scholar
• Chappuis B, Braun M, Stettler C, et al. Differential effects of pioglitazone and rosiglitazone on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392-9
   PubMed Web of Science ®Google Scholar
• Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44
   PubMedGoogle Scholar
• Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized, controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Wilcox R, Bousser MG, Betteridge D, for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73
   PubMed Web of Science ®Google Scholar
• Erdmann E, Wilcox R, Perez A, et al. Mortality after serious heart failure: results from PROactive. J Am Coll Cardiol 2007;(Suppl.):66A [abstract 1016-65]
   Google Scholar
• Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab 2007;9:23-30
   PubMed Web of Science ®Google Scholar
• Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Int J Clin Pract 2007;61:1160-9
   PubMed Web of Science ®Google Scholar
• Deeks ED, Keam SJ. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2007;67:2747-79
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, et al. For the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-80
   PubMed Web of Science ®Google Scholar
• Irons BK, Greene RS, Mazzolini TA, et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006;26:168-81
   PubMed Web of Science ®Google Scholar
• Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc 2008;83:333-42
   PubMed Web of Science ®Google Scholar
• Araki T, Emoto M, Teramura M, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metab Clin Exp 2006;55:996-1001
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92
   PubMed Web of Science ®Google Scholar
• Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LeBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73
   PubMed Web of Science ®Google Scholar
• Nissen SE; PERISCOPE Investigators. Effect of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. Presented at the 57th annual Scientific Session of the American College of Cardiology. March 31, 2008. Presentation number 407-13
   Google Scholar
• Rosen CJ. The rosiglitazone story – lessons from an FDA advisory committee meeting. N Engl J Med 2007;357:844-6
   PubMed Web of Science ®Google Scholar
• Gerrits CM, Bhatacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16:1314-6
   Google Scholar
• Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007;357:28-38
   PubMed Web of Science ®Google Scholar
• Avandia [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; August 2007
   Google Scholar
• GlaxoSmithKline. Avandia cardiovascular event modeling project study No.: HM2006/00497/00/WEUSRTP866: coronary heart disease outcomes in patients receiving antidiabetic agents [study No.: ZM2005/00181/01]. Available at http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf [accessed May 5, 2008]
   Google Scholar
• European Medicines Agency. EMEA recommends new warnings and contraindications for rosiglitazone [press release]. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/avaglim/4223208en.pdf [accessed May 5, 2008]
   Google Scholar
• GlaxoSmithKline. Health Canada endorsed important safety information on rosiglitazone [public communication]. Available at http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/avandia_pc-cp_4_e.pdf [accessed May 5, 2008]
   Google Scholar
• ACTOS [prescribing information]. Deerfield (IL): Takeda Pharmaceuticals America, Inc.; September 2007
   Google Scholar
• Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140-5
   PubMed Web of Science ®Google Scholar
• Guan YF, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPAR-gamma stimulation of EnaC-mediated renal sodium absorption. Nat Med 2005;11:861-6
   PubMed Web of Science ®Google Scholar
• Tang WH. Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006;73:390-7
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, et al. On behalf of the PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-8
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Dear Healthcare professional letter re: clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus, February 2007. Available at http://www.fda.gov/MedWatch/SAFETY/2007/Avandia_GSK_Ltr.pdf [accessed July 29, 2008]
   Google Scholar
• Takeda Pharmaceuticals, Inc. Dear Healthcare professional letter re: observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus, March 2007. Available at http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf [accessed July 29, 2008]
   Google Scholar
• Efficacy study of pioglitazone HCL on bone metabolism in postmenopausal women with impaired fasting glucose. Available at http://www.clinicaltrials.gov/ct2/show/NCT00708175?term=pioglitazone&rank=1 [accessed July 28, 2008]
   Google Scholar
• Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. Available at http://www.clinicaltrials.gov/ct2/show/NCT00679939?term=rosiglitazone+and+bone&rank=2 [accessed July 28, 2008]
   Google Scholar
• Barnett AH. Insulin-sensitizing agents – thiazolidinediones (glitazones). Curr Med Res Opin 2002;18(Suppl. 1):S31-S39
   PubMedGoogle Scholar
• Scheen AJ. Glitazones and weight gain. Ann Endocrinol (Paris) 2002;63:IS412-IS414
   Google Scholar
• Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000;22:1395-409
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptides. Diabetes 1998;47:159-69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005;62:173-81
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
   PubMed Web of Science ®Google Scholar
• Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-7
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-53
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied improved glycemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5 years. 67th Scientific Sessions of the American Diabetes Association. Chicago, Illinois, June 22–26, 2007 [poster 557-P]
   Google Scholar
• Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-105
   Google Scholar
• Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
   PubMed Web of Science ®Google Scholar
• DeFronzo F. Results of the ACTos NOW for the Prevention of Diabetes Study (ACTNOW). Presented at the 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, June 8, 2008
   Google Scholar